WO2004074320A3 - Nouvelles cibles therapeutiques pour le cancer - Google Patents

Nouvelles cibles therapeutiques pour le cancer Download PDF

Info

Publication number
WO2004074320A3
WO2004074320A3 PCT/US2004/004730 US2004004730W WO2004074320A3 WO 2004074320 A3 WO2004074320 A3 WO 2004074320A3 US 2004004730 W US2004004730 W US 2004004730W WO 2004074320 A3 WO2004074320 A3 WO 2004074320A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
present
provides
therapeutic targets
detection
Prior art date
Application number
PCT/US2004/004730
Other languages
English (en)
Other versions
WO2004074320A2 (fr
WO2004074320A8 (fr
Inventor
David W Morris
Marc S Malandro
Original Assignee
Sagres Discovery Inc
David W Morris
Marc S Malandro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/367,094 external-priority patent/US20040170982A1/en
Priority claimed from US10/388,838 external-priority patent/US20040180344A1/en
Priority claimed from US10/417,375 external-priority patent/US20040219528A1/en
Priority claimed from US10/461,862 external-priority patent/US7767387B2/en
Priority claimed from US10/663,431 external-priority patent/US20070218071A1/en
Priority claimed from US10/737,318 external-priority patent/US20050202442A1/en
Priority to JP2006503661A priority Critical patent/JP2009520459A/ja
Priority to CA002516128A priority patent/CA2516128A1/fr
Priority to US10/545,777 priority patent/US20060228710A1/en
Application filed by Sagres Discovery Inc, David W Morris, Marc S Malandro filed Critical Sagres Discovery Inc
Priority to AU2004213432A priority patent/AU2004213432A1/en
Priority to EP04711933A priority patent/EP1594893A2/fr
Publication of WO2004074320A2 publication Critical patent/WO2004074320A2/fr
Publication of WO2004074320A8 publication Critical patent/WO2004074320A8/fr
Publication of WO2004074320A3 publication Critical patent/WO2004074320A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne de nouvelles séquences à utiliser pour la détection, pour le diagnostic et pour le traitement de cancers, en particulier de lymphomes. L'invention concerne des séquences polynucléotidiques associées au cancer (CA), dont l'expression est associée au cancer. L'invention concerne des polypeptides CA associés au cancer, situés sur la surface cellulaire, et de nouvelles cibles thérapeutiques contre le cancer. L'invention concerne également des compositions et des méthodes de diagnostic pour la détection du cancer. L'invention concerne des anticorps monoclonaux et polyclonaux spécifiques aux polypeptides CA. L'invention concerne également des outils de diagnostic, des compositions et des méthodes thérapeutiques pour le criblage, la prévention et le traitement du cancer.
PCT/US2004/004730 2003-02-14 2004-02-17 Nouvelles cibles therapeutiques pour le cancer WO2004074320A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP04711933A EP1594893A2 (fr) 2003-02-14 2004-02-17 Cibles therapeutiques pour le cancer
AU2004213432A AU2004213432A1 (en) 2003-02-14 2004-02-17 Novel therapeutic targets in cancer
JP2006503661A JP2009520459A (ja) 2003-02-14 2004-02-17 癌における治療標的
US10/545,777 US20060228710A1 (en) 2003-02-14 2004-02-17 Novel therapeutic targets in cancer
CA002516128A CA2516128A1 (fr) 2003-02-14 2004-02-17 Nouvelles cibles therapeutiques pour le cancer

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US10/367,094 US20040170982A1 (en) 2003-02-14 2003-02-14 Novel therapeutic targets in cancer
US10/367,094 2003-02-14
US10/388,838 2003-03-14
US10/388,838 US20040180344A1 (en) 2003-03-14 2003-03-14 Novel therapeutic targets in cancer
US10/417,375 2003-04-15
US10/417,375 US20040219528A1 (en) 2003-04-15 2003-04-15 Novel therapeutic targets in cancer
US10/461,862 US7767387B2 (en) 2003-06-13 2003-06-13 Therapeutic targets in cancer
US10/461,862 2003-06-13
US10/663,431 US20070218071A1 (en) 2003-09-15 2003-09-15 Novel therapeutic targets in cancer
US10/663,431 2003-09-15
US10/737,318 2003-12-15
US10/737,318 US20050202442A1 (en) 2003-12-15 2003-12-15 Novel therapeutic targets in cancer

Publications (3)

Publication Number Publication Date
WO2004074320A2 WO2004074320A2 (fr) 2004-09-02
WO2004074320A8 WO2004074320A8 (fr) 2004-12-09
WO2004074320A3 true WO2004074320A3 (fr) 2005-06-02

Family

ID=32913375

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/004730 WO2004074320A2 (fr) 2003-02-14 2004-02-17 Nouvelles cibles therapeutiques pour le cancer

Country Status (6)

Country Link
US (1) US20060228710A1 (fr)
EP (2) EP1594893A2 (fr)
JP (2) JP2009520459A (fr)
AU (1) AU2004213432A1 (fr)
CA (1) CA2516128A1 (fr)
WO (1) WO2004074320A2 (fr)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE445701T1 (de) 2000-11-28 2009-10-15 Zymogenetics L L C Zytokine rezeptor zcytor19
WO2003089603A2 (fr) * 2002-04-19 2003-10-30 Zymogenetics, Inc. Recepteur de cytokine
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
US7767387B2 (en) * 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
SI3404102T1 (sl) 2004-04-21 2021-11-30 Alexion Pharmaceuticals, Inc. Konjugati za dodajanje kostem in njihova uporaba za ciljanje beljakovin na kosti
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
AU2005286607B2 (en) 2004-09-23 2011-01-27 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2006055927A2 (fr) * 2004-11-17 2006-05-26 The Cleveland Clinic Foundation Gene et proteine pathogenes associes a la dyskinesie paroxystique et a l'epilepsie
EP1817059A2 (fr) 2004-12-01 2007-08-15 Genentech, Inc. Conjugues medicament anticorps et procedes correspondants
CN101257920B (zh) * 2005-06-21 2012-09-05 塞莱克蒂斯股份有限公司 与抗前列腺癌疫苗有关的方法和组合物
AU2006291054B2 (en) 2005-09-12 2011-10-13 The Brigham And Women's Hospital, Inc. Recurrent gene fusions in prostate cancer
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
EP1920366A1 (fr) 2006-01-20 2008-05-14 Glenbrook Associates, Inc. Système et procédé pour base de données optimisée à contexte riche pour traitement de concepts
WO2008026010A1 (fr) 2006-08-29 2008-03-06 Oxford Genome Sciences (Uk) Ltd Identification d'une protéine associée à un carcinome hépatocellulaire, à un glioblastome et à un cancer du poumon
WO2008069621A1 (fr) * 2006-12-08 2008-06-12 Korea Research Institute Of Bioscience And Biotechnology Nouvelle utilisation de gènes mig12 et pio5
US8362224B2 (en) * 2006-12-19 2013-01-29 The Trustees Of The University Of Pennsylvania Screening for CD93 (C1qRp)-associated polymorphism(S) in the diagnosis, prevention and treatment of autoimmune diseases
WO2008128144A2 (fr) * 2007-04-15 2008-10-23 Shuang Zhang Système de sélection d'anticorps monoclonal, et fabrication et utilisation de celui-ci
EP2171094B1 (fr) 2007-07-06 2011-11-16 The Regents of the University of Michigan Réarrangements de gènes mipol1 -etv1
GB0714842D0 (en) * 2007-07-31 2007-09-12 Imp Innovations Ltd Methods
WO2009020521A2 (fr) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification et traitement de tumeurs de la prostate répondant aux œstrogènes
DE102008045696A1 (de) * 2008-09-04 2010-03-11 Drk Blutspendedienst West Ggmbh Granulozyten HNA-3a/b-Antigen
EP2392352B1 (fr) * 2009-01-28 2017-10-25 Korea Research Institute of Bioscience and Biotechnology Utilisation de cd93 ou d'un fragment soluble de celui-ci
EA028336B1 (ru) 2009-03-05 2017-11-30 МЕДАРЕКС Л.Л.Си. Полностью человеческие антитела, специфические в отношении cadm1
KR101962476B1 (ko) 2009-07-03 2019-03-26 아비펩 피티와이 리미티트 면역성 접합체 및 그 제조방법
US8470980B2 (en) 2009-09-09 2013-06-25 Centrose, Llc Extracellular targeted drug conjugates
AU2010295689B2 (en) 2009-09-17 2014-02-13 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
EP2516462B1 (fr) 2009-12-23 2015-05-06 Avipep Pty Ltd Immuno-conjugués et leurs méthodes de production
CA2796571C (fr) 2010-04-13 2019-10-29 Celldex Therapeutics Inc. Anticorps qui se lient au cd27 humain et utilisations de ceux-ci
DK2528625T3 (da) 2010-04-15 2013-10-14 Spirogen Sarl Pyrrolobenzodiazepiner og konjugater deraf
CN114246952A (zh) 2010-06-08 2022-03-29 基因泰克公司 半胱氨酸改造的抗体和偶联物
US20120121615A1 (en) 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
WO2012088608A1 (fr) 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions contenant des peptides natriurétiques et leurs méthodes d'utilisation
US20130330349A1 (en) 2011-02-23 2013-12-12 Rappaport Family Institute For Research In The Medical Sciences High affinity molecules capable of binding a type a plexin receptor and uses of same
EP3103810A3 (fr) 2011-04-21 2017-03-08 Garvan Institute of Medical Research Molécules à domaine variable modifié et procédés de préparation et d'utilisation de celles-ci
ES2567276T3 (es) 2011-05-12 2016-04-21 Genentech, Inc. Método de LC-MS/MS de monitoreo de múltiples reacciones para detectar anticuerpos terapéuticos en muestras de animales usando péptidos de cambio de marco
CN103987407B (zh) 2011-10-14 2016-08-24 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其偶联物
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
CA2867299C (fr) 2012-03-15 2019-08-27 John Chen Anticorps anti-cd27 humains, leurs procedes et leurs utilisations
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
JP6392763B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ ピロロベンゾジアゼピン−抗体結合体
ES2660029T3 (es) 2012-10-12 2018-03-20 Medimmune Limited Conjugados de anticuerpo-pirrolobenzodiazepinas
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
MX364327B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina - anti-cd22.
CA2885340C (fr) 2012-10-12 2016-11-08 Spirogen Sarl Pyrrolobenzodiazepines et leurs conjugues
RS57694B1 (sr) 2012-10-12 2018-11-30 Adc Therapeutics Sa Pirolobenzodiazepin - anti-psma konjugati antitela
HUE039329T2 (hu) 2012-10-12 2018-12-28 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
ES2658888T5 (es) 2012-12-21 2021-10-19 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas
WO2014096365A1 (fr) 2012-12-21 2014-06-26 Spirogen Sàrl Dimères de pyrrolobenzodiazépines asymétriques à utiliser dans le traitement de maladies prolifératives et auto-immunes
JP6340019B2 (ja) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
AU2014230735B2 (en) 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
EA201690195A1 (ru) 2013-08-12 2016-05-31 Дженентек, Инк. Конъюгатные соединения антитело-лекарство на основе димера 1-(хлорметил)-2,3-дигидро-1h-бензо[e]индола и способы применения и лечения
WO2015052532A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépines
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
PE20161394A1 (es) 2013-12-16 2017-01-06 Genentech Inc Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco
MX371092B (es) 2013-12-16 2020-01-16 Genentech Inc Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos.
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック， インコーポレイテッド １−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
WO2016007873A1 (fr) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions et méthodes de traitement de la craniosynostose
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3191134B1 (fr) 2014-09-12 2019-11-20 Genentech, Inc. Intermédiaires disulfure d'anthracycline, conjugué anticorps-médicaments et procédés
BR112017003236A2 (pt) 2014-09-12 2017-11-28 Genentech Inc anticorpos elaborados com cisteína, conjugados de droga e anticorpos, método de preparação de conjugado de droga e anticorpo e composição farmacêutica
CR20170099A (es) 2014-09-17 2017-07-19 Genentech Inc Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas
MX2017006770A (es) 2014-11-25 2018-02-09 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepina y anticuerpo.
EP3226909A1 (fr) 2014-12-03 2017-10-11 Genentech, Inc. Composés d'amine quaternaire et conjugués anticorps-médicament de ceux-ci
MX2017007392A (es) 2014-12-05 2019-01-24 Alexion Pharma Inc Tratamiento de convulsiones con fosfatasa alcalina recombinante.
EP3250227A2 (fr) 2015-01-28 2017-12-06 Alexion Pharmaceuticals, Inc. Méthodes de traitement d'un sujet atteint d'une déficience en phosphatase alcaline
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
RU2745528C2 (ru) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
US11229686B2 (en) 2015-09-28 2022-01-25 Alexion Pharmaceuticals, Inc. Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
EP3436020A4 (fr) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. Méthodes de traitement de l'hypophosphatasie chez les adolescents et les adultes
RU2754558C2 (ru) 2016-04-01 2021-09-03 Алексион Фармасьютикалз, Инк. Лечение мышечной слабости с помощью щелочных фосфатаз
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
WO2017214130A1 (fr) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Impact du métal sur la production des phosphatases alcalines
WO2017214024A1 (fr) 2016-06-06 2017-12-14 Genentech, Inc. Médicaments conjugués d'anticorps silvestrol et procédés d'utilisation
US10912287B2 (en) * 2016-06-28 2021-02-09 Biocytogen Pharmaceuticals (Beijing) Co., Ltd Genetically modified mice expressing humanized PD-1
WO2018031662A1 (fr) 2016-08-11 2018-02-15 Genentech, Inc. Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
WO2018065501A1 (fr) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Procédés de préparation de conjugués anticorps-médicament
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
AU2017371517B2 (en) * 2016-12-09 2023-01-05 Onk Therapeutics Limited Engineered natural killer cells and uses thereof
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
PT3544636T (pt) 2017-02-08 2021-05-04 Medimmune Ltd Conjugados de anticorpos-pirrolobenzodiazepinas
KR20190129058A (ko) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
WO2018192944A1 (fr) 2017-04-18 2018-10-25 Medimmune Limited Conjugués de pyrrolobenzodiazépine
KR20190141666A (ko) 2017-04-20 2019-12-24 에이디씨 테라퓨틱스 에스에이 항-axl 항체-약물 접합체로의 병용 요법
AU2018285562B2 (en) 2017-06-14 2024-01-18 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
ES2906965T3 (es) 2017-08-18 2022-04-21 Medimmune Ltd Conjugados de pirrolobenzodiazepina
WO2019060398A1 (fr) 2017-09-20 2019-03-28 Ph Pharma Co., Ltd. Analogues de thailanstatine
WO2019072241A1 (fr) 2017-10-13 2019-04-18 Beijing Biocytogen Co., Ltd Animal non humain génétiquement modifié avec pd-1 humain ou chimérique
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
WO2019190752A1 (fr) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Production de glycoprotéines
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP7466459B2 (ja) 2018-04-17 2024-04-12 セルデックス セラピューティクス インコーポレイテッド 抗ｃｄ２７および抗ｐｄ－ｌ１抗体ならびに二重特異性構築物
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
TW202037381A (zh) 2018-10-24 2020-10-16 瑞士商赫孚孟拉羅股份公司 綴合化學降解誘導劑及使用方法
WO2020123275A1 (fr) 2018-12-10 2020-06-18 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN114507695B (zh) * 2022-02-17 2023-09-19 四川大学华西医院 一种用于调控神经元活性的重组载体和方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057497A2 (fr) * 2001-01-18 2002-07-25 The Regents Of The University Of California Clonage de protooncogenes a rendement eleve
US20020132237A1 (en) * 2000-05-26 2002-09-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2003039443A2 (fr) * 2001-11-05 2003-05-15 Deutsches Krebsforschungszentrum Nouveaux marqueurs genetiques pour leucemies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7724398A (en) * 1997-06-06 1998-12-21 Regents Of The University Of California, The A melanoma associated antigen, t cell epitopes thereof and methods of using sa me
US6345375B1 (en) * 1999-02-24 2002-02-05 California Amplifier, Inc. Packet-based communication methods and systems having improved data throughput
US7705120B2 (en) * 2001-06-21 2010-04-27 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132237A1 (en) * 2000-05-26 2002-09-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002057497A2 (fr) * 2001-01-18 2002-07-25 The Regents Of The University Of California Clonage de protooncogenes a rendement eleve
WO2003039443A2 (fr) * 2001-11-05 2003-05-15 Deutsches Krebsforschungszentrum Nouveaux marqueurs genetiques pour leucemies

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ARIHIRO K ET AL: "Significance of alpha 9 beta 1 and alpha v beta 6 integrin expression in breast carcinoma.", BREAST CANCER (TOKYO, JAPAN) JAN 2000, vol. 7, no. 1, January 2000 (2000-01-01), pages 19 - 26, XP008038846, ISSN: 1340-6868 *
AUGENLICHT L H ET AL: "CLONING AND SCREENING OF SEQUENCES EXPRESSED IN A MOUSE COLON TUMOR", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 42, no. 3, March 1982 (1982-03-01), pages 1088 - 1093, XP000929512, ISSN: 0008-5472 *
BERNS A: "PROVIRUS TAGGING AS AN INSTRUMENT TO IDENTIFY ONCOGENES AND TO ESTABLISH SYNERGISM BETWEEN ONCOGENES", ARCHIVES OF VIROLOGY, NEW YORK, NY, US, vol. 102, no. 1/2, 1988, pages 1 - 18, XP008012759, ISSN: 0304-8608 *
HIBI KENJI ET AL: "Aberrant upregulation of a novel integrin alpha subunit gene at 3p21.3 in small cell lung cancer", ONCOGENE, vol. 9, no. 2, 1994, pages 611 - 619, XP008038818, ISSN: 0950-9232 *
JONKERS JOS ET AL: "Retroviral insertional mutagenesis as a strategy to identify cancer genes", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1287, no. 1, 1996, pages 29 - 57, XP008038878, ISSN: 0006-3002 *
KHAN J ET AL: "EXPRESSION PROFILING IN CANCER USING CDNA MICROARRAYS", ELECTROPHORESIS, WEINHEIM, DE, vol. 20, no. 2, February 1999 (1999-02-01), pages 223 - 229, XP008002229, ISSN: 0173-0835 *
LI J ET AL: "Leukaemia disease genes: Large-scale cloning and pathway predictions", NATURE GENETICS, NATURE AMERICA, NEW YORK, US, vol. 23, no. 3, November 1999 (1999-11-01), pages 348 - 353, XP002223354, ISSN: 1061-4036 *
MIKKERS H ET AL: "HIGH-THROUGHPUT RETROVIRAL TAGGING TO IDENTIFY COMPONENTS OF SPECIFIC SIGNALING PATHWAYS IN CANCER", NATURE GENETICS, NEW YORK, NY, US, vol. 32, September 2002 (2002-09-01), pages 153 - 159,I,331, XP001148101, ISSN: 1061-4036 *
PALMER ELISE L ET AL: "Sequence and tissue distribution of the integrin alpha-9 subunit, a novel partner of beta-1 that is widely distributed in epithelia and muscle", JOURNAL OF CELL BIOLOGY, vol. 123, no. 5, 1993, pages 1289 - 1297, XP002305856, ISSN: 0021-9525 *
ZHANG L ET AL: "Gene expression profiles in normal and cancer cells", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 276, 23 May 1997 (1997-05-23), pages 1268 - 1272, XP002083785, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
JP2009520459A (ja) 2009-05-28
AU2004213432A1 (en) 2004-09-02
EP2196474A3 (fr) 2010-12-15
WO2004074320A2 (fr) 2004-09-02
CA2516128A1 (fr) 2004-09-02
EP1594893A2 (fr) 2005-11-16
JP2010263894A (ja) 2010-11-25
EP2196474A2 (fr) 2010-06-16
US20060228710A1 (en) 2006-10-12
WO2004074320A8 (fr) 2004-12-09

Similar Documents

Publication Publication Date Title
WO2004074320A8 (fr) Nouvelles cibles therapeutiques pour le cancer
WO2005031001A3 (fr) Nouvelles cibles therapeutiques pour le traitement du cancer
WO2005104810A3 (fr) Nouveaux cibles therapeutiques dans le cancer
WO2004058146A3 (fr) Nouvelles compositions et nouveaux procedes de traitement du cancer
WO2004060304A3 (fr) Compositions et procedes pour la cancerotherapie
WO2005107396A3 (fr) Compositions et procedes nouveaux dans le domaine du cancer
WO2006119365A3 (fr) Compositions et procedes destines au diagnostic et au traitement du cancer
WO2006029219A3 (fr) Anticorps monoclonaux humains anti-ctla4 dans le traitement du cancer
WO2005080431A3 (fr) Anticorps monoclonaux bloquant specifiquement l'activite biologique d'un antigene tumoral
WO2003048328A3 (fr) Anticorps contre l'antigene tumoral de l'anhydrase carbonique ix (ca ix)
WO2004100870A3 (fr) Compositions et procedes d'immunotherapie specifique a wt1
IL171356A (en) Anti-interferon receptor antibody for treatment of inflammatory bowel disease
TW200626900A (en) Wnt proteins and detection and treatment of cancer
TW200626899A (en) Frizzled proteins and detection and treatment of cancer
WO2004067570A3 (fr) Diagnostic et traitement du cancer de la prostate
WO2006038955A3 (fr) Nouvelles cibles therapeutiques contre le cancer
WO2003080808A3 (fr) Nouvelles compositions et nouveaux procedes pour le cancer
WO2005085861A3 (fr) Acides nucleiques et polypeptides codes destines a etre utilises dans des troubles hepatiques et du cancer epithelial
WO2009019365A3 (fr) Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal
WO2007033167A3 (fr) Compositions et methodes de detection et de traitement du cancer
WO2001018046A3 (fr) Sequences de tumeurs ovariennes et procedes d'utilisation correspondants
WO2007107774A3 (fr) Nouvelles méthodes de diagnostic et de traitement
WO2005058251A3 (fr) Anticorps specifiques de hla-dr, compositions et methodes associees
WO2004060301A3 (fr) Nouvelles compositions et procedes utilises dans le cadre du cancer
WO2004029287A3 (fr) Polypeptides et acides nucleiques codant ceux-ci et utilisation de ceux-ci pour la prevention, le diagnostic ou le traitement de troubles du foie et du cancer epithelial

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 36/2004 UNDER (72, 75) REPLACE "MORRIS, DAVID, W. [US/US]; 2841 EMERALD BAY DRIVE, DAVIS, CA 95616 (US).MORRIS, DAVID, W. [US/US]; 2841 EMERALD BAY DRIVE, DAVIS, CA 95616 (US)." BY "MORRIS, DAVID, W. [US/US]; 2841 EMERALD BAY DRIVE, DAVIS, CA 95616 (US)."

WWE Wipo information: entry into national phase

Ref document number: 2516128

Country of ref document: CA

Ref document number: 2004213432

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006503661

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004213432

Country of ref document: AU

Date of ref document: 20040217

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004213432

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004711933

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004711933

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006228710

Country of ref document: US

Ref document number: 10545777

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10545777

Country of ref document: US